Effectiveness of Antibiotic Therapy for Exacerbations of Chronic Obstructive Pulmonary Disease (TRANCE)
Situations That do Not Require Antibiotics for Acute Exacerbations of Mild-to-moderate Chronic Obstructive Pulmonary Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Catalonia
-
Barcelona, Catalonia, Spain, 08036
- Hospital Clinic
-
Barcelona, Catalonia, Spain, 08038
- Primary Healthcare Center La Marina
-
Figueres, Catalonia, Spain, 17600
- Primary Healthcare Center Figueres
-
Girona, Catalonia, Spain, 17003
- Primary Healthcare Center Montilivi
-
Girona, Catalonia, Spain, 17007
- Primary Healthcare Center Girona-4
-
Hostalric, Catalonia, Spain, 17450
- Primary Healthcare Centre Breda-Hostalric
-
Lleida, Catalonia, Spain, 25001
- Primary Healthcare Center Lleida
-
Molins de Rey, Catalonia, Spain, 08750
- Primary Healthcare Centre Molins de Rei
-
Olot, Catalonia, Spain, 17800
- Primary Healthcare Centre Olot
-
Reus, Catalonia, Spain, 43203
- Primary Healthcare Center Reus-3
-
Tarragona, Catalonia, Spain, 43003
- Primary Healthcare Center Les Muralles
-
Tarragona, Catalonia, Spain, 43005
- Primary Healthcare Centre Jaume I
-
Valls, Catalonia, Spain, 43600
- Primary Healthcare Center Valls Urbà
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Acute exacerbations (at least one criterion present: increase of dyspnoea, increase of sputum production and/or increase of purulence) of
- patients older than 40 years old,
- smokers or ex-smokers of more than 10 pack-years,
- with COPD and FEV1 greater than 50%, diagnosed by spirometry and a predicted ratio FEV1/FVC<0.7%.
Exclusion Criteria:
- Severe COPD (FEV1<50%)
- Pneumonia
- Active neoplasm
- Tracheotomy
- Criteria for hospitalisation
- Patients previously being on antibiotics
- Immunodepressed patients
- History of hypersensitivity to beta-lactams or intolerance to clavulanate
- Enrollment in other clinical trials
- Patients who refuse to take part in this study
- Patients who have not had a spirometry test for the past two years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo pills t.i.d. for 8 days
|
One pill to be taken every eight hours for 8 days
Other Names:
|
|
Active Comparator: Amoxycillin and clavulanic acid
Amoxycillin and clavulanate t.i.d. for 8 days
|
500-125 mg to be taken every eight hours for 8 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Patients Who Were Cured
Time Frame: Day 9-11
|
Cure defined as the disappearance of the acute signs and symptoms related to the infection, with complete return to the previous situation of stability
|
Day 9-11
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Days Till the Next Exacerbation
Time Frame: One year
|
For the assessment of the time till next exacerbation patients were monitored over a period of 365 days on a three-monthly basis.
Patients were instructed to contact their physician immediately if there was any change in their health status.
Diagnosis of a new exacerbation was based on the same clinical criteria described previously.
For the calculation of time to the next exacerbation, all clinical failures occurring during therapy were counted as zero exacerbation-free interval days.
|
One year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Carl Llor, Doctor, Catalan Society of Family Medicine
- Study Director: Marc Miravitlles, Doctor, Hospital Clinic
- Study Director: Ana Moragas, Family doc., Catalan Society of Family Medicine
Publications and helpful links
General Publications
- Miravitlles M, Moragas A, Hernandez S, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest. 2013 Nov;144(5):1571-1577. doi: 10.1378/chest.13-0518.
- Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Oct 15;186(8):716-23. doi: 10.1164/rccm.201206-0996OC. Epub 2012 Aug 23.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P06/31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.